Recombinant 9-valent Human Papillomavirus vaccine (Recbio)

Biological E, an Indian pharmaceutical manufacturer, has partnered with China’s Recbio to produce and commercialize the REC603 HPV9 vaccine, marking a significant step in combating HPV-related cancers. Designed to protect against nine strains of Human Papillomavirus (HPV), the vaccine targets cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. Globally, HPV infections are linked to 620,000 cancer cases in women and 70,000 in men annually. Under the agreement, Recbio will supply drug substances and transfer technology for formulation, filling, and packaging to Biological E. This collaboration also grants Biological E access to global tender markets, including UNICEF and the Pan American Health Organization (PAHO). Recbio’s REC603 is currently undergoing Phase III clinical trials in China and is designed for individuals aged 9 to 45. Large-scale manufacturing by Biological E in India will begin after the technology transfer, ensuring affordable doses for both domestic and international markets. Dr. Liu Yong, CEO of Recbio, stated, “This partnership accelerates the global availability of the HPV9 vaccine, addressing the growing demand for more affordable cervical cancer prevention solutions.” This agreement positions Recbio for international expansion while leveraging Biological E’s manufacturing expertise to improve vaccine accessibility worldwide.

Hyderabad: Chinese biopharmaceutical company ,Jiangsu Recbio Technology Company Limited (02179.HK) has entered into a licensing and technology transfer agreement with Biological E . Limited (BE), an Indian vaccine and pharmaceutical manufacturer, for the production and commercialisation of its recombinant 9-valent HPV (HPV9) vaccine, REC603. Under the agreement, Recbio will supply the drug substance (DS) and transfer the formulation, filling, and packaging technology to BE.The agreement also grants BE rights to participate in global tenders issued by UNICEF and the Pan American Health Organization (PAHO). The HPV9 vaccine is designed to protect against nine strains of human papillomavirus associated with cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts.In 2019, HPV infections were linked to an estimated 620,000 cancer cases in women and 70,000 in men globally. Designed for individuals aged 9 to 45, Recbio’s REC603 is currently in Phase III clinical trials in China. Once the technology transfer is complete, BE will begin large-scale production in India, aiming to improve domestic access and supply affordable doses to global markets. Recbio has initiated the transfer of technical know-how, materials, and documentation to enable local production by BE. The company will continue to support BE through clinical development and regulatory processes to ensure timely market entry. The collaboration comes amid growing global demand for affordable cervical cancer prevention . Leveraging BE’s manufacturing capacity, the partnership aims to improve HPV vaccine availability in India and other regions Dr. Liu Yong, Founder, Chairman, and CEO of Recbio, expressed confidence in the partnership, stating, “This cooperation marks significant progress for Recbio’s international expansion. Together with BE, we aim to accelerate the launch of the HPV9 vaccine in India and globally.” Large-scale manufacturing is expected to commence following the completion of the technology transfer. The agreement represents Recbio’s entry into the Indian and global vaccine markets and underscores its expansion in the field of innovative immunizations. By Online Bureau ,